Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2022; 13(7): 532-542
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.532
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.532
Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patients
Yun-Fei Li, Qian Ren, Chao-Hui Sun, Li Li, Rui-Xue Sun, Xian Su, Hua Yu, Department of Ophthalmology, Shijiazhuang City People’s Hospital, Shijiazhuang 050031, Hebei Province, China
Hai-Dong Lian, Department of Ophthalmology, The First Affiliated Hospital of Shihezi University School of Medicine, Shihezi 832061, Xinjiang Uygur Autonomous Region, China
Author contributions: Li YF and Yu H designed this study; Li YF wrote this manuscript; Li YF, Ren Q, Sun ZH, Li L, Lian HD, Sun RX, Sun X and Yu H were responsible for sorting the data; and all authors read and confirmed the revision of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Shijiazhuang City People’s Hospital Institutional Review Board (Approval No. 2017-22).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors have nothing to disclose.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qian Ren, MD, Associate Chief Physician, Department of Ophth-almology, Shijiazhuang City People’s Hospital, No. 365 Jianhua South Street, Yuhua District, Shijiazhuang 050031, Hebei Province, China. qr31535@163.com
Received: February 17, 2022
Peer-review started: February 17, 2022
First decision: April 17, 2022
Revised: April 26, 2022
Accepted: June 16, 2022
Article in press: June 16, 2022
Published online: July 15, 2022
Peer-review started: February 17, 2022
First decision: April 17, 2022
Revised: April 26, 2022
Accepted: June 16, 2022
Article in press: June 16, 2022
Published online: July 15, 2022
Core Tip
Core Tip: The main pathological feature of diabetic macular edema (DME) is abnormal neovascularization throughout the retinal pigment epithelium. New vessels develop rapidly and are fragile, thus resulting to rupture and retinal detachment, macular edema, impaired, vision and blind spots. Without effective treatment, vision declines rapidly, causing irreversible impairment. Compaq has a strong affinity with vascular endothelial growth factor (VEGF) receptors, and as a novel VEGF biological agent, it has a relatively strong inhibition of vascular growth in ocular lesions. Our study investigated the effect and mechanism of anti-VEGF drugs in DME patients to improve clinical DME treatment.